Thymosin Alpha-1 Side Effects: Potentially Permanent Adverse Events Explained

Does thymosin alpha-1 cause permanent side effects?

No permanent adverse effect has been established, and that is not the same as proving it cannot happen. The available trial findings do not settle whether thymosin alpha-1 can cause permanent side effects.

What exists is short-term tolerability data: hepatitis trials, an FDA adverse-event database search that returned zero reports as of April 22, 2024 [1], and a 2026 Cochrane review in which the peptide may have caused fewer serious adverse events than comparison treatments, on low-certainty evidence [2].

What the trials show

The 2026 Cochrane review pooled 10 randomized trials with 1,349 adults who had chronic hepatitis B, published between 1991 and 2018 [2]. Thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious ones (RR 0.47, 95% CI 0.27 to 0.83; very low certainty) [2]. The reviewers said they are not sure the peptide helps hepatitis B at all [2].

The broadest safety claim comes from authors tied to the manufacturer: more than 4,400 people enrolled in trials and more than 17 million doses given after marketing, with adverse experiences described as 'infrequent and mild' [1]. Read that as company-linked data. A 12-person placebo-controlled pilot, in which 7 people received thymosin fraction 5 or thymosin alpha-1 and 5 received placebo, reported no significant side effects in either group [5]. It was too small to detect rare effects.

What the Zadaxin label says to watch for

Zadaxin is the finished 1.6 mg injection sold outside the US [1]. The Italian label says it is given subcutaneously or intramuscularly twice weekly for 4 weeks from the first vaccination, repeated from week 8 to week 12. It lists pregnancy and breastfeeding as contraindications and advises caution in people with allergies or autoimmune disease and in those taking other immune-modulating drugs [1]. No US-approved dose exists [1].

The label's autoimmune caution is a precaution, not a record of harm.

Why permanence is hard to judge here

Thymosin alpha-1 is not FDA-approved. FDA's December 2024 review notes four US orphan drug designations, which are a separate process from approval and not approvals themselves [1].

In healthy volunteers the peptide peaked at about 0.7 to 2 hours and cleared with a half-life of about 1.8 to 2.6 hours, with no accumulation after five daily doses [3][1]. Half-life describes how long the peptide stays in the blood, not how long an immune response lasts.

FDA's compounding page still carries its safety concerns about the peptide even though it now sits in the 'nominated but withdrawn' table: significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information the agency called inadequate to understand the extent of any safety issues [6]. In December 2024 an FDA advisory committee voted 4 yes and 17 no on adding it to the pharmacy bulks list, with members who voted no citing no compelling evidence of clinical effectiveness and safety [4].